Objectives: To measure preferences and willingness to pay (WTP) for a novel anaesthetic (dental gel) versus existing anaesthetic options for periodontal maintenance visits. Design: The study was conducted by developing and administering a survey, composed of a modified decision aid and a WTP...

Stated preference (SP) surveys attempt to obtain monetary values for non-market goods that reflect individuals’ “true” preferences. Numerous empirical studies suggest that monetary values from SP studies are sensitive to survey design and so may not reflect respondents’ true preferences....

The recognition that environmental hazards can affect children differently and more severely than adults has provoked growing concern in industrialized nations about the impact of environmental pollution on children’s health. In this paper, commissioned by the OECD, we are charged with...

This article evaluates the cost effectiveness of and patients' willingness to pay for interventions by community pharmacists in the overall context of pharmaceutical care. The rationale for interventions by pharmacists in patient care is examined from the viewpoint of clinical and economic needs...

Objective: To measure the economic value of a new insulin formulation consisting of rapid-acting insulin lispro and intermediate-acting neutral protamine lispro in a 25 : 75 ratio (Humalog(R) Mix 25(TM)). Design and Setting: A cost-benefit analysis using a consumer-based willingness-to-pay (WTP)...

Objective: To estimate the willingness to pay for a new chemotherapy, raltitrexed (Tomudex(TM) ) over conventional therapy with fluorouracil plus leucovorin (FU-LV) from the perspective of patients with advanced colorectal cancer. The study was part of the product's reimbursement application in...

Objective:The primary objective was to evaluate the relationship between willingness-to-pay (WTP), quality-of-life (QOL), and disease-severity measures in patients with asthma. The hypothesis studied was that patients with asthma with more severe disease are willing to pay more for a...

Background: The cost effectiveness of hepatitis A prevention is typically assessed by comparing vaccination costs with the number of life-years saved. This endpoint does not consider the benefits of preventing nonfatal yet symptomatic infections. Nearly as many days of healthy life are lost to...